Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066970 | 1.00 | ALDH1A1 (0.53) | ALDH1A1EPHX1TDP1SMN1; SMN2SPHK1 | |
| SCHEMBL267044 | 0.98 | ALDH1A1 (0.50) | ALDH1A1EPHX1TDP1SMN1; SMN2 | |
| SCHEMBL4733581 | 0.96 | ALDH1A1 (0.48) | ALDH1A1EPHX1TDP1SMN1; SMN2 | |
| SCHEMBL3298839 | 0.92 | ALDH1A1 (0.47) | ALDH1A1EPHX1TDP1SMN1; SMN2 | |
| SCHEMBL28320505 | 0.89 | ALDH1A1 (0.46) | ALDH1A1EPHX1SMN1; SMN2 | |
| SCHEMBL3797776 | 0.86 | ALDH1A1 (0.43) | ALDH1A1EPHX1 | |
| SCHEMBL28467561 | 0.86 | ALDH1A1 (0.41) | ALDH1A1EPHX1TDP1SMN1; SMN2SPHK1 | |
| SCHEMBL17372324 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1EPHX1TDP1SMN1; SMN2 | |
| SCHEMBL31313174 | 0.86 | EPHX1 (0.56) | ALDH1A1EPHX1 | |
| SCHEMBL10465601 | 0.86 | ALDH1A1 (0.55) | ALDH1A1EPHX1TDP1SMN1; SMN2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2624066-B1 | CHARGING MEMBER AND METHOD FOR PRODUCING SAME | CANON KK (JP) | 2016-03-16 | — | — | EP | claimed |
| US-6433041-B1 | — | — | None | — | — | US | disclosed |
| US-20260103603-A1 | AQUEOUS COATING COMPOSITION AND PROCESS FOR PREPARING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12600811-B2 | Crosslinking agent composition for water-compatible resin, and water-compatible resin composition | NISSHINBO CHEMICAL INC. (JP) | 2026-04-14 | — | — | US | disclosed |
| EP-4083143-B1 | CROSSLINKING AGENT COMPOSITION FOR WATER-COMPATIBLE RESIN, AND WATER-COMPATIBLE RESIN COMPOSITION | NISSHINBO CHEMICAL INC (JP) | 2025-12-24 | — | — | EP | disclosed |
| EP-4301836-B1 | FUNCTIONALIZED MACROPARTICLES OF MESOPOROUS SILICA FOR PROTEIN STABILIZATION AND METAL REMOVAL FROM A BEVERAGE | ESSECO S R L (IT) | 2025-02-12 | — | — | EP | disclosed |
| US-20240425718-A1 | UNDERFILL COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-12-26 | — | — | US | disclosed |
| US-20240076591-A1 | FUNCTIONALIZED MACROPARTICLES OF MESOPOROUS SILICA FOR PROTEIN STABILIZATION AND METAL REMOVAL FROM A BEVERAGE | ENARTIS S.R.L. (IT) | 2024-03-07 | — | — | US | disclosed |
| EP-4301836-A1 | FUNCTIONALIZED MACROPARTICLES OF MESOPOROUS SILICA FOR PROTEIN STABILIZATION AND METAL REMOVAL FROM A BEVERAGE | Esseco S.r.l. (IT) | 2024-01-10 | — | — | EP | disclosed |
| US-20230203317-A1 | AQUEOUS COATING COMPOSITION AND PROCESS FOR PREPARING THE SAME | DOW GLOBAL TECHNOLOGIES LLC | 2023-06-29 | — | — | US | disclosed |
| EP-1130046-B1 | Method for producing suspension of crosslinked silicone particles | DOW CORNING TORAY SILICONE (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-6437042-B2 | COMPRISES POLYSILOXANE, CROSSLINKER, AND CONDENSATION CATALYST EMULSIFIED IN WATER USING SURFACTANT; METALLIZATION; PARTICLE DIAMETER; DISPERSION | DOW CORNING TORAY SILICONE CO., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| US-6433041-B2 | CROSSLINKED SILICONES; WEAR RESISTANT PROTECTIVE COATINGS | DOW CORNING TORAY SILICONE CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20020055557-A1 | Water base coating material composition and production process | DOW TORAY CO., LTD. (JP) | 2002-05-09 | — | — | US | disclosed |
| EP-1186641-A2 | Water base coating material composition and production process | Dow Corning Toray Silicone Co., Ltd. (JP) | 2002-03-13 | — | — | EP | disclosed |
| EP-1132443-A9 | Method for producing water based coating compositions | Dow Corning Toray Silicone Company, Ltd. (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-20010027233-A1 | Method for producing suspension of crosslinked silicone particles | DOW TORAY CO., LTD. (JP) | 2001-10-04 | — | — | US | disclosed |
| US-20010025080-A1 | Method for producing water based coating compositions | DOW TORAY CO., LTD. (JP) | 2001-09-27 | — | — | US | disclosed |
| EP-1130046-A2 | Method for producing suspension of crosslinked silicone particles | Dow Corning Toray Silicone Co., Ltd. (JP) | 2001-09-05 | — | — | EP | disclosed |
| EP-1122703-A2 | Amusement system having typing practice function, typing practice system, and computer readable storage medium | Konami Co., Ltd. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600811-B2 | Crosslinking agent composition for water-compatible resin, and water-compatible resin composition | COL2A1, COL1A1, COL14A1 | ALDH1A1 320/4885EPHX1 215/4885TDP1 2655/4885 |
| US-20260103603-A1 | AQUEOUS COATING COMPOSITION AND PROCESS FOR PREPARING THE SAME | ARCN1, CD14, PUF60 | ALDH1A1 4715/4885EPHX1 3047/4885TDP1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.